[Development of molecular targeted therapy for hematological disorder in the era of genomic drug discovery].
The next generation sequencing technologies has provided unprecedented opportunities for high-through-put genomic research. These technologies have been applied to hematological disorders in a variety of contexts and have provided genetic landscape of each disorder in details including the identification of disease specific driver mutations and subsequent chances of drug discovery targeting the pathogenetic lesions. On the other hand, the development of molecular targeted therapies has been successful in only limited fields to date. In this prospect we will review the current situation of molecular targeted therapy against several hematological diseases and discuss about the future challenges to promote drug discovery based on the enormous genomic information.